Evidence map›Paper›PMID 38514629›Full record

ArticleNature communications2024

Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms.

Ryuichiro Yagi, Shinichi Goto, Yukihiro Himeno, Yoshinori Katsumata, Masahiro Hashimoto, Calum A MacRae, Rahul C Deo

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07163767 (Acute Myocardial Infarction Prediction Using Artificial Intelligence Applied to Electrocardiogram Images), which is not on this map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
21.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07163767 active not recruitingnot on this mapstarted 2025, after this paper: background citation

Acute Myocardial Infarction Prediction Using Artificial Intelligence Applied to Electrocardiogram Images

TypeobservationalSponsorGuangdong Provincial People's HospitalRan2025 to 2028Enrolled150,000ConditionsAcute Myocardial Infarction (AMI), Electrocardiography, Artifical IntelligenceArmsDeep learning approach of ECG for AMI detection
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Risk-guided cardioprotection in cardio-oncology.Nature cardiovascular research · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Integrated Cardio-oncology Service.Cardiac failure review · 2026
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ryuichiro Yagi *One Brave Idea and Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Shinichi Goto *One Brave Idea and Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0450-0331
Yukihiro HimenoDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Yoshinori KatsumataInstitute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan.
Masahiro HashimotoDepartment of Radiology, Keio University School of Medicine, Tokyo, Japan.
Calum A MacRaeOne Brave Idea and Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5181-2664
Rahul C DeoOne Brave Idea and Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. rdeo@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-2791-9434
Brigham and Women's Hospital · USKeio University · JP

Funding

American Heart Association (American Heart Association, Inc.) One Brave Idea
6 · The paper itself

Abstract

Anthracyclines can cause cancer therapy-related cardiac dysfunction (CTRCD) that adversely affects prognosis. Despite guideline recommendations, only half of the patients undergo surveillance echocardiograms. An AI model detecting reduced left ventricular ejection fraction from 12-lead electrocardiograms (ECG) (AI-EF model) suggests ECG features reflect left ventricular pathophysiology. We hypothesized that AI could predict CTRCD from baseline ECG, leveraging the AI-EF model's insights, and developed the AI-CTRCD model using transfer learning on the AI-EF model. In 1011 anthracycline-treated patients, 8.7% experienced CTRCD. High AI-CTRCD scores indicated elevated CTRCD risk (hazard ratio (HR), 2.66; 95% CI 1.73-4.10; log-rank p < 0.001). This remained consistent after adjusting for risk factors (adjusted HR, 2.57; 95% CI 1.62-4.10; p < 0.001). AI-CTRCD score enhanced prediction beyond known factors (time-dependent AUC for 2 years: 0.78 with AI-CTRCD score vs. 0.74 without; p = 0.005). In conclusion, the AI model robustly stratified CTRCD risk from baseline ECG.

Indexed as

Antineoplastic AgentsHeart DiseasesVentricular Dysfunction, LeftAnthracyclinesAntibiotics, AntineoplasticArtificial IntelligenceCardiotoxicityElectrocardiographyHumansStroke VolumeVentricular Function, LeftAnthracyclinesAntibiotics, AntineoplasticAntineoplastic Agents

Identifiers

PMID38514629
PMCPMC10957877
OpenAlexW4393063908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.